|
First-Line Chemotherapy Regimen Showed Clinically Relevant Survival Differences in Specific Histology Types of Advanced Non-Small Cell Lung Cancer INDIANAPOLIS, Sept.
|
|
... wonders if Regina is the new home of a rare type of prostate cancer. A biopsy in May revealed that Steinson has small cell neuroendocrine carcinoma of the prostate. "My urologist said that it's very rare -- it's a small cell type of cancer which ...
|
|
Drugs of today , Vol. 41, No. 12. , pp. 773-784. response Abstract Tumor survival, growth and metastasis depend on efficient tumor cell proliferation and tumor angiogenesis, and targeting both of these ...
|
|
... response to the subsequent standard chemoradiation compared to placebo in a Phase II study of advanced squamous cell carcinoma of the head and neck (SCCHN). [1] These encouraging results, presented during the 33rd Congress of the European Society ...
|
|
Main Category: GastroIntestinal / Gastroenterology Also Included In: Radiology / Nuclear Medicine Pancreatic carcinoma is an obstinate disease that is difficult to deal with, the five-year survival rate is 4%. ...
|
|
... Oncology (ASTRO) in Boston that a newer, minimally invasive approach to treating high risk patients with Stage I non-small cell lung carcinoma (NSCLC) may significantly reduce the risk of local disease recurrence. Developed at AGH over the past ...
|
|
Main Category: Lung Cancer Also Included In: Radiology / Nuclear Medicine ; Clinical Trials / Drug Trials Article Date: 24 Sep 2008 - 0:00 PDT Radiation oncologists at Allegheny General Hospital in Pittsburgh ...
|
|
Developed at AGH over the past decade, the procedure involves removing only the cancerous section of the lung and enveloping the surgical site in a mesh material that is embedded with radioactive seeds.
|
|
... vessels 4. Hair changes 5. Unexplained itch Lumps and bumps Xanthelesmata is a common condition in which yellowish small flat lumps appear around the eyes. This is often a sign of raised blood cholesterol levels, especially if it is extensive and ...
|
|
Pfizer updated safety and efficacy results for its investigational compound CP-751,871 in patients with non-small cell lung cancer .
|